Focused On-demand Library for Elongation factor-like GTPase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Elongation factor Tu GTP-binding domain-containing protein 1; Elongation factor-like 1; Protein FAM42A

Alternative UPACC:

Q7Z2Z2; A6NKY5; B7Z6I0; Q9H8Z6


Elongation factor-like GTPase 1, also known as Elongation factor Tu GTP-binding domain-containing protein 1, Elongation factor-like 1, and Protein FAM42A, plays a crucial role in protein synthesis. It is involved in the biogenesis of the 60S ribosomal subunit and translational activation of ribosomes, facilitating the GTP-dependent release of EIF6 from 60S pre-ribosomes in the cytoplasm. This process is essential for activating ribosomes for translation competence, allowing 80S ribosome assembly, and facilitating EIF6 recycling to the nucleus for 60S rRNA processing and nuclear export.

Therapeutic significance:

Elongation factor-like GTPase 1's involvement in Shwachman-Diamond syndrome 2, characterized by hematopoietic abnormalities, exocrine pancreatic dysfunction, and skeletal dysplasia, highlights its potential as a therapeutic target. Understanding the role of Elongation factor-like GTPase 1 could open doors to potential therapeutic strategies for treating this autosomal recessive disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.